in Newswire Published on April 7, 2022

AbbVie Facing Class Action Following Stock Price Drops Linked to Xeljanz, Rinvoq Safety Concerns

Nakata v. AbbVie Inc. et al.

Filed: April 6, 2022 § 1:22-cv-01773

AbbVie faces a class action that alleges the pharma co. misled investors by “condition[ing]” them to believe Rinvoq was far safer than Xeljanz.

Case Spotlight

Hair Relaxer Lawsuits

ClassAction.org Newsletter

Stay Current

Sign Up For
Our Newsletter

New cases and investigations, settlement deadlines, and news straight to your inbox.

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on April 7, 2022 — 4:46 PM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Senior Managing Editor of ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.